Associated tags: Clinical trial, Patient, CNS, Central nervous system, Neuroscience, Cumulus cloud, Medical imaging, Health, EEG, Doctor of Philosophy, Dementia, Memory, Language, MD, Caregiver, Diagnosis, Medical device, Neurology, Biomarker, Cognition, Alzheimer's disease
Locations: UK, NORTHERN IRELAND, NORTH AMERICA, WASHINGTON, NEW YORK, NETHERLANDS, MASSACHUSETTS
Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
Key Points:
- Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
- Patients who received weekly XPro™ treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p
- Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer’s Disease.
- EEG's capability to assess brain function makes these findings particularly noteworthy for INmune Bio’s novel treatment strategy.
Retrieved on:
Wednesday, February 7, 2024
Lead,
Caregiver,
Patient,
PA Consulting Group,
CNS,
Physician,
Code,
Drug development,
GOOD,
EEG,
Health,
Doctor of Philosophy,
Innovation,
Medical imaging BELFAST, Northern Ireland and CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has been recognized by GOOD DESIGN® Awards, in the medical category for the product design of its first-in-class electroencephalogram (EEG) headset. A key component of the Cumulus Neuroassessment Platform, the current version of the 16 lead dry-sensor EEG headset – used to obtain clinical-grade data in remote settings to monitor and evaluate neurological activity – was designed by PA Consulting, taking cues from the garment industry to ensure ease of mind for users by hiding advanced technology underneath water resistant finishes and providing an easily wearable, yet durable, product. The headset synchronizes with tablet-based functional assessments for use in-clinic or unsupervised (at-home/remote) environments, allowing for increased ease-of-use for patients, caregivers, and clinical research teams.
Key Points:
- Recognized for its Patient Centric Solutions and State-of-the-Art Technology, the Medical-Grade Cumulus EEG Headset Wins Third Award in 2023 for Innovative Design While Advancing Clinical Neuroscience Research
BELFAST, Northern Ireland and CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has been recognized by GOOD DESIGN® Awards , in the medical category for the product design of its first-in-class electroencephalogram (EEG) headset.
- The headset synchronizes with tablet-based functional assessments for use in-clinic or unsupervised (at-home/remote) environments, allowing for increased ease-of-use for patients, caregivers, and clinical research teams.
- The GOOD DESIGN® Award is the oldest and most prestigious awards program for the most innovative and cutting-edge industrial, product, and graphic designs produced around the world.
- The Cumulus Neuroassessment Platform, which includes our EEG headset, removes those barriers entirely.
Retrieved on:
Wednesday, February 7, 2024
Lead,
Caregiver,
Patient,
PA Consulting Group,
CNS,
Physician,
Code,
Drug development,
GOOD,
EEG,
Health,
Doctor of Philosophy,
Innovation,
Medical imaging BELFAST, Northern Ireland and CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has been recognized by GOOD DESIGN® Awards, in the medical category for the product design of its first-in-class electroencephalogram (EEG) headset. A key component of the Cumulus Neuroassessment Platform, the current version of the 16 lead dry-sensor EEG headset – used to obtain clinical-grade data in remote settings to monitor and evaluate neurological activity – was designed by PA Consulting, taking cues from the garment industry to ensure ease of mind for users by hiding advanced technology underneath water resistant finishes and providing an easily wearable, yet durable, product. The headset synchronizes with tablet-based functional assessments for use in-clinic or unsupervised (at-home/remote) environments, allowing for increased ease-of-use for patients, caregivers, and clinical research teams.
Key Points:
- Recognized for its Patient Centric Solutions and State-of-the-Art Technology, the Medical-Grade Cumulus EEG Headset Wins Third Award in 2023 for Innovative Design While Advancing Clinical Neuroscience Research
BELFAST, Northern Ireland and CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has been recognized by GOOD DESIGN® Awards , in the medical category for the product design of its first-in-class electroencephalogram (EEG) headset.
- The headset synchronizes with tablet-based functional assessments for use in-clinic or unsupervised (at-home/remote) environments, allowing for increased ease-of-use for patients, caregivers, and clinical research teams.
- The GOOD DESIGN® Award is the oldest and most prestigious awards program for the most innovative and cutting-edge industrial, product, and graphic designs produced around the world.
- The Cumulus Neuroassessment Platform, which includes our EEG headset, removes those barriers entirely.
Retrieved on:
Wednesday, October 25, 2023
AD,
Life,
Behavior,
Pathology,
Amnesia,
Doctor of Philosophy,
CNS,
Deficit spending,
Health,
Clinical trial,
Personality,
Poster,
Dementia,
Memory,
Confusion,
University,
Language,
Patient,
Communication,
Cognition,
Medical device,
Medical imaging,
Alzheimer's disease,
Disease,
Cumulus cloud Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.
Key Points:
- Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.
- BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting on Wednesday October 25th in Boston, Massachusetts.
- Cumulus presented three poster presentations, two featuring internally generated data collected from Cumulus-sponsored studies partnering with academic and clinical institutions, and one featuring data generated from a study sponsored by INmune Bio Inc. (Nasdaq: INMB) a clinical stage biopharma company.
- Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.
Retrieved on:
Tuesday, October 10, 2023
TMS,
Doctor of Philosophy,
Neuropsychiatry,
European College of Neuropsychopharmacology,
Memory,
Health,
EEG,
FDA,
Data collection,
MRI,
Learning,
LTP,
CNS,
ECNP,
Patient,
Medical imaging,
Cumulus cloud At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity
Key Points:
- At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity
BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from a feasibility pilot study at the European College of Neuropsychopharmacology (ECNP) Annual Meeting in Barcelona, Spain on October 10th.
- Using the proprietary Cumulus Neuroassessment Platform to gather data via repeated at-home sampling, the study was conducted on behalf of a biopharma study sponsor.
- LTP is a synaptic plasticity phenomenon related to learning and memory which is used widely in animal studies.
- Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.
Retrieved on:
Tuesday, October 10, 2023
TMS,
Doctor of Philosophy,
Neuropsychiatry,
European College of Neuropsychopharmacology,
Memory,
Health,
EEG,
FDA,
Data collection,
MRI,
Learning,
LTP,
CNS,
ECNP,
Patient,
Medical imaging,
Cumulus cloud At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity
Key Points:
- At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity
BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from a feasibility pilot study at the European College of Neuropsychopharmacology (ECNP) Annual Meeting in Barcelona, Spain on October 10th.
- Using the proprietary Cumulus Neuroassessment Platform to gather data via repeated at-home sampling, the study was conducted on behalf of a biopharma study sponsor.
- LTP is a synaptic plasticity phenomenon related to learning and memory which is used widely in animal studies.
- Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.
Communication,
University,
Clinic,
Sleep,
Data collection,
Bristol Myers Squibb,
Boston University,
Biomarker,
Language,
CNS,
Wakefulness,
Trial of the century,
Amel Association International,
Doctor of Philosophy,
Dementia,
MD,
Patient,
Collection,
EEG,
Amnesia,
Confusion,
Neurology,
Personality,
Boston University Chobanian & Avedisian School of Medicine,
AD,
Health,
Function (mathematics),
Memory,
Conference,
Behavior,
Medical imaging,
Medical device,
Alzheimer's disease,
Medicine,
Cumulus cloud BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
Key Points:
- BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
- Purely digital markers are scalable but lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus.
- Importantly, the remote data captured in this study was of similar quality to data generated using traditional methods in house at Boston University."
- Dr. Budson and his team receive funding and other resources from Bristol Myers Squibb and Cumulus Neuroscience.
Communication,
University,
Clinic,
Sleep,
Data collection,
Bristol Myers Squibb,
Boston University,
Biomarker,
Language,
CNS,
Wakefulness,
Trial of the century,
Amel Association International,
Doctor of Philosophy,
Dementia,
MD,
Patient,
Collection,
EEG,
Amnesia,
Confusion,
Neurology,
Personality,
Boston University Chobanian & Avedisian School of Medicine,
AD,
Health,
Function (mathematics),
Memory,
Conference,
Behavior,
Medical imaging,
Medical device,
Alzheimer's disease,
Medicine,
Cumulus cloud BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
Key Points:
- BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
- Purely digital markers are scalable but lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus.
- Importantly, the remote data captured in this study was of similar quality to data generated using traditional methods in house at Boston University."
- Dr. Budson and his team receive funding and other resources from Bristol Myers Squibb and Cumulus Neuroscience.
Communication,
University Hospitals Bristol and Weston NHS Foundation Trust,
University,
Psychology,
Pathology,
Innovation,
Research,
Biomarker,
Language,
CNS,
North Bristol NHS Trust,
Behavior,
Associate,
Doctor of Philosophy,
UKCA,
Fastball,
Patient,
Physician,
EEG,
NIHR,
Amnesia,
Neurology,
Confusion,
Diagnosis,
Personality,
NHS,
AD,
FDA,
Health,
Oscillation,
Memory,
Caregiver,
Disease,
Pharmaceutical industry,
Medical imaging,
Medical device,
Nursing,
Alzheimer's disease,
Dementia,
Bristol,
Cumulus cloud Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.
Key Points:
- Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.
- Importantly, as a passive test, performance is not impacted by anxiety level, education level or language.
- They have also demonstrated that this response changes when a person develops dementia, offering hope for its potential as a breakthrough for earlier diagnosis.
- We are honored to partner with the Universities of Bath and Bristol on this important study."
Communication,
University Hospitals Bristol and Weston NHS Foundation Trust,
University,
Psychology,
Pathology,
Innovation,
Research,
Biomarker,
Language,
CNS,
North Bristol NHS Trust,
Behavior,
Associate,
Doctor of Philosophy,
UKCA,
Fastball,
Patient,
Physician,
EEG,
NIHR,
Amnesia,
Neurology,
Confusion,
Diagnosis,
Personality,
NHS,
AD,
FDA,
Health,
Oscillation,
Memory,
Caregiver,
Disease,
Pharmaceutical industry,
Medical imaging,
Medical device,
Nursing,
Alzheimer's disease,
Dementia,
Bristol,
Cumulus cloud Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.
Key Points:
- Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.
- Importantly, as a passive test, performance is not impacted by anxiety level, education level or language.
- They have also demonstrated that this response changes when a person develops dementia, offering hope for its potential as a breakthrough for earlier diagnosis.
- We are honored to partner with the Universities of Bath and Bristol on this important study."
